{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:41:30Z","timestamp":1794505290631,"version":"4.9.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["DP5OD031828"],"award-info":[{"award-number":["DP5OD031828"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007038","name":"Lung Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metastatic solid tumors remain the principal cause of cancer mortality worldwide. High tumor burden impairs responses to chimeric antigen receptor (CAR) T cell therapy, yet off-tumor toxicity limits the doses that can be safely delivered. Strategies to selectively enhance CAR T cell activity at tumor sites could widen the therapeutic window. Using syngeneic models of extensive metastatic lung adenocarcinoma and melanoma, we show that 8\u2009Gy of tumor irradiation significantly enhanced CAR T cell persistence in a manner critically dependent on dendritic cells (DCs). Irradiation promoted trogocytic antigen dressing of tumor antigens onto DCs, which then expanded CAR T cells through the chimeric receptor. Without functional DCs, irradiation failed to sustain CAR T cell persistence and tumors relapsed. Irradiation increased CAR T cell numbers within tumors but not in adjacent normal lung tissue that also expressed target antigen, conferring robust control of tumor without increased toxicity. These data define a mechanistic basis and rationale for combining radiotherapy with CAR T cell therapy.<\/jats:p>","DOI":"10.1038\/s43018-026-01167-6","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:03:05Z","timestamp":1779440585000},"page":"1104-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases"],"prefix":"10.1038","volume":"7","author":[{"given":"Sophia","family":"Navarre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki N.","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achuth","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Reyes-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Belabed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4726-7012","authenticated-orcid":false,"given":"Laszlo","family":"Halasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-1635","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Mattiuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merouane","family":"Ounadjela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertrude","family":"Gunset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2889-1397","authenticated-orcid":false,"given":"Jorge","family":"Mansilla-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Feucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Cabriolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Le Berichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Birbrair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-1190","authenticated-orcid":false,"given":"Justin","family":"Eyquem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-8778","authenticated-orcid":false,"given":"Brian D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4481-7827","authenticated-orcid":false,"given":"Miriam","family":"Merad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-8025","authenticated-orcid":false,"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1965-4069","authenticated-orcid":false,"given":"Jalal","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1167_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR3","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","volume":"30","author":"H Hubbeling","year":"2024","unstructured":"Hubbeling, H. et al. Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma. Clin. Cancer Res. 30, 5083\u20135093 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1167_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1167_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Riviere, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"1167_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"1167_CR7","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas, A. R. et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol. Ther. 27, 1919\u20131929 (2019).","journal-title":"Mol. Ther."},{"key":"1167_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41587-019-0083-5","volume":"37","author":"B J\u00fcrgens","year":"2019","unstructured":"J\u00fcrgens, B. & Clarke, N. S. Evolution of CAR T-cell immunotherapy in terms of patenting activity. Nat. Biotechnol. 37, 370\u2013375 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1167_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311\u2013325 (2017).","journal-title":"Cancer Cell"},{"key":"1167_CR10","doi-asserted-by":"publisher","first-page":"7340","DOI":"10.1158\/1078-0432.CCR-18-3199","volume":"25","author":"N Lapteva","year":"2019","unstructured":"Lapteva, N. et al. T-cell receptor stimulation enhances the expansion and function of CD19 chimeric antigen receptor-expressing T cells. Clin. Cancer Res. 25, 7340\u20137350 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1167_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin, L. et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci. Transl. Med. 14, eabn2231 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1167_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.aay5967","volume":"367","author":"K Reinhard","year":"2020","unstructured":"Reinhard, K. et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367, 446\u2013453 (2020).","journal-title":"Science"},{"key":"1167_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162\u2013168 (2019).","journal-title":"Science"},{"key":"1167_CR14","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"1167_CR15","first-page":"2346","volume":"55","author":"BE Bejcek","year":"1995","unstructured":"Bejcek, B. E. et al. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Cancer Res. 55, 2346\u20132351 (1995).","journal-title":"Cancer Res."},{"key":"1167_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier, B. et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580, 257\u2013262 (2020).","journal-title":"Nature"},{"key":"1167_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-021-03651-8","volume":"595","author":"M Casanova-Acebes","year":"2021","unstructured":"Casanova-Acebes, M. et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature 595, 578\u2013584 (2021).","journal-title":"Nature"},{"key":"1167_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/HP.0b013e31826386ef","volume":"103","author":"IL Jackson","year":"2012","unstructured":"Jackson, I. L. et al. A preclinical rodent model of radiation-induced lung injury for medical countermeasure screening in accordance with the FDA animal rule. Health Phys. 103, 463\u2013473 (2012).","journal-title":"Health Phys."},{"key":"1167_CR19","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/jnci\/dji139","volume":"97","author":"WF Hartsell","year":"2005","unstructured":"Hartsell, W. F. et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J. Natl Cancer Inst. 97, 798\u2013804 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"1167_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127\u2013132 (2020).","journal-title":"Nature"},{"key":"1167_CR21","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1182\/bloodadvances.2024012599","volume":"8","author":"N Kostopoulos","year":"2024","unstructured":"Kostopoulos, N. et al. Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration. Blood Adv. 8, 6308\u20136320 (2024).","journal-title":"Blood Adv."},{"key":"1167_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05829-6","volume":"14","author":"M Sugita","year":"2023","unstructured":"Sugita, M. et al. Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell Death Dis. 14, 305 (2023).","journal-title":"Cell Death Dis."},{"key":"1167_CR23","first-page":"121","volume":"1846","author":"D Heylmann","year":"2014","unstructured":"Heylmann, D., R\u00f6del, F., Kindler, T. & Kaina, B. Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells. Biochim. Biophys. Acta 1846, 121\u2013129 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"1167_CR24","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1097\/BRS.0b013e3181b8b6f5","volume":"34","author":"PC Gerszten","year":"2009","unstructured":"Gerszten, P. C., Mendel, E. & Yamada, Y. Radiotherapy and radiosurgery for metastatic spine disease. Spine 34, S78\u2013S92 (2009).","journal-title":"Spine"},{"key":"1167_CR25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/0008-5472.CAN-16-1387","volume":"77","author":"E Tassi","year":"2017","unstructured":"Tassi, E. et al. Early effector T lymphocytes coexpress multiple inhibitory receptors in primary non-small cell lung cancer. Cancer Res. 77, 851\u2013861 (2017).","journal-title":"Cancer Res."},{"key":"1167_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41586-022-05672-3","volume":"614","author":"M Sorin","year":"2023","unstructured":"Sorin, M. et al. Single-cell spatial landscapes of the lung tumour immune microenvironment. Nature 614, 548\u2013554 (2023).","journal-title":"Nature"},{"key":"1167_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","volume":"593","author":"BI Reinfeld","year":"2021","unstructured":"Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282\u2013288 (2021).","journal-title":"Nature"},{"key":"1167_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41590-023-01475-4","volume":"24","author":"MD Park","year":"2023","unstructured":"Park, M. D. et al. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat. Immunol. 24, 792\u2013801 (2023).","journal-title":"Nat. Immunol."},{"key":"1167_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1084\/jem.20101688","volume":"208","author":"A Chow","year":"2011","unstructured":"Chow, A. et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J. Exp. Med. 208, 261\u2013271 (2011).","journal-title":"J. Exp. Med."},{"key":"1167_CR30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.immuni.2013.04.004","volume":"38","author":"D Hashimoto","year":"2013","unstructured":"Hashimoto, D. et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38, 792\u2013804 (2013).","journal-title":"Immunity"},{"key":"1167_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","volume":"39","author":"M Cabeza-Cabrerizo","year":"2021","unstructured":"Cabeza-Cabrerizo, M., Cardoso, A., Minutti, C. M., Pereira da Costa, M. & Reis e Sousa, C. Dendritic cells revisited. Annu. Rev. Immunol. 39, 131\u2013166 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"1167_CR32","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022\u20131037 (2018).","journal-title":"Cell"},{"key":"1167_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41577-020-00413-x","volume":"21","author":"DA Anderson","year":"2021","unstructured":"Anderson, D. A., Dutertre, C.-A., Ginhoux, F. & Murphy, K. M. Genetic models of human and mouse dendritic cell development and function. Nat. Rev. Immunol. 21, 101\u2013115 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1167_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41577-022-00675-7","volume":"22","author":"F Ginhoux","year":"2022","unstructured":"Ginhoux, F., Guilliams, M. & Merad, M. Expanding dendritic cell nomenclature in the single-cell era. Nat. Rev. Immunol. 22, 67\u201368 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1167_CR35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.20120030","volume":"209","author":"AT Satpathy","year":"2012","unstructured":"Satpathy, A. T. et al. Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages. J. Exp. Med. 209, 1135\u20131152 (2012).","journal-title":"J. Exp. Med."},{"key":"1167_CR36","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1084\/jem.20112675","volume":"209","author":"MM Meredith","year":"2012","unstructured":"Meredith, M. M. et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J. Exp. Med. 209, 1153\u20131165 (2012).","journal-title":"J. Exp. Med."},{"key":"1167_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08201-x","volume":"10","author":"A Czechowicz","year":"2019","unstructured":"Czechowicz, A. et al. Selective hematopoietic stem cell ablation using CD117-antibody\u2013drug-conjugates enables safe and effective transplantation with immunity preservation. Nat. Commun. 10, 617 (2019).","journal-title":"Nat. Commun."},{"key":"1167_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nri2020","volume":"7","author":"DM Davis","year":"2007","unstructured":"Davis, D. M. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat. Rev. Immunol. 7, 238\u2013243 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"1167_CR39","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8\u03b1+ dendritic cells in cytotoxic T cell immunity. Science 322, 1097\u20131100 (2008).","journal-title":"Science"},{"key":"1167_CR40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723 (2017).","journal-title":"Cancer Cell"},{"key":"1167_CR41","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon, H. et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924\u2013938 (2016).","journal-title":"Immunity"},{"key":"1167_CR42","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"1167_CR43","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat. Med. 24, 572\u2013579 (2018).","journal-title":"Nat. Med."},{"key":"1167_CR44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","volume":"35","author":"PTH Went","year":"2004","unstructured":"Went, P. T. H. et al. Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 35, 122\u2013128 (2004).","journal-title":"Hum. Pathol."},{"key":"1167_CR45","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/bjc.1987.276","volume":"56","author":"G Moldenhauer","year":"1987","unstructured":"Moldenhauer, G., Momburg, F., M\u00f6ller, P., Schwartz, R. & H\u00e4mmerling, G. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br. J. Cancer 56, 714\u2013721 (1987).","journal-title":"Br. J. Cancer"},{"key":"1167_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1806009","volume":"9","author":"D Qin","year":"2020","unstructured":"Qin, D. et al. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. OncoImmunology 9, 1806009 (2020).","journal-title":"OncoImmunology"},{"key":"1167_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava, S. et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell 39, 193\u2013208 (2021).","journal-title":"Cancer Cell"},{"key":"1167_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45307-x","volume":"15","author":"K Mani","year":"2024","unstructured":"Mani, K. et al. Causes of death among people living with metastatic cancer. Nat. Commun. 15, 1519 (2024).","journal-title":"Nat. Commun."},{"key":"1167_CR49","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"1167_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52913-z","volume":"9","author":"F Guisier","year":"2019","unstructured":"Guisier, F., Cousse, S., Jeanvoine, M., Thiberville, L. & Salaun, M. A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer. Sci. Rep. 9, 16902 (2019).","journal-title":"Sci. Rep."},{"key":"1167_CR51","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph, R. W. et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin. Cancer Res. 24, 4960\u20134967 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1167_CR52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1074-7613(00)00026-1","volume":"13","author":"HL Hanson","year":"2000","unstructured":"Hanson, H. L. et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13, 265\u2013276 (2000).","journal-title":"Immunity"},{"key":"1167_CR53","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1158\/2326-6066.CIR-21-1075","volume":"10","author":"AR S\u00e1nchez-Paulete","year":"2022","unstructured":"S\u00e1nchez-Paulete, A. R. et al. Targeting macrophages with CAR T cells delays solid tumor progression and enhances anti-tumor immunity. Cancer Immunol. Res. 10, 1354\u20131369 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"1167_CR54","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1182\/blood-2024-208472","volume":"144","author":"CR D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo, C. R. et al. A prospective clinical trial of boom-boom radiation as bridging therapy for patients with large B-cell lymphoma undergoing treatment with lisocabtagene maraleucel (liso-cel) therapy. Blood 144, 3126\u20133126 (2024).","journal-title":"Blood"},{"key":"1167_CR55","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s43018-021-00245-1","volume":"2","author":"Y Ban","year":"2021","unstructured":"Ban, Y. et al. Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer. Nat. Cancer 2, 919\u2013931 (2021).","journal-title":"Nat. Cancer"},{"key":"1167_CR56","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","volume":"402","author":"JY Chang","year":"2023","unstructured":"Chang, J. Y. et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402, 871\u2013881 (2023).","journal-title":"Lancet"},{"key":"1167_CR57","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.ijrobp.2023.11.040","volume":"118","author":"MF Bassetti","year":"2024","unstructured":"Bassetti, M. F. et al. Combining dual checkpoint immunotherapy with ablative radiation to all sites of oligometastatic non-small cell lung cancer: toxicity and efficacy results of a phase 1b trial. Int. J. Radiat. Oncol. Biol. Phys. 118, 1481\u20131489 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1167_CR58","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR59","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2643-3230.BCD-23-0263","volume":"5","author":"G Mo","year":"2024","unstructured":"Mo, G. et al. Long-term remissions following CD20-directed chimeric antigen receptor\u2013adoptive T-cell therapy. Blood Cancer Discov. 5, 258\u2013266 (2024).","journal-title":"Blood Cancer Discov."},{"key":"1167_CR60","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","volume":"7","author":"EL Smith","year":"2019","unstructured":"Smith, E. L. et al. BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy. Cancer Immunol. Res. 7, 1047\u20131053 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1167_CR61","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","volume":"11","author":"D Alizadeh","year":"2021","unstructured":"Alizadeh, D. et al. IFN\u03b3 is critical for CAR T cell-mediated myeloid activation and induction of endogenous immunity. Cancer Discov. 11, 2248\u20132265 (2021).","journal-title":"Cancer Discov."},{"key":"1167_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003351","volume":"9","author":"E Conde","year":"2021","unstructured":"Conde, E. et al. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants. J. Immunother. Cancer 9, e003351 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1167_CR63","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn, N. F. et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473\u2013488 (2019).","journal-title":"Cancer Cell"},{"key":"1167_CR64","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","volume":"34","author":"SL Goff","year":"2016","unstructured":"Goff, S. L. et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J. Clin. Oncol. 34, 2389\u20132397 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1167_CR65","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1074-7613(02)00365-5","volume":"17","author":"S Jung","year":"2002","unstructured":"Jung, S. et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17, 211\u2013220 (2002).","journal-title":"Immunity"},{"key":"1167_CR66","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11307-007-0104-5","volume":"9","author":"CFM Molthoff","year":"2007","unstructured":"Molthoff, C. F. M. et al. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2\u2032-deoxy-2\u2032-[18F]fluoro-d-glucose (FDG) and 3\u2032-[18F]fluoro-3\u2032-deoxythymidine (FLT). Mol. Imaging Biol. 9, 340\u2013347 (2007).","journal-title":"Mol. Imaging Biol."},{"key":"1167_CR67","first-page":"2118","volume":"32","author":"K Kubota","year":"1991","unstructured":"Kubota, K. et al. Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. J. Nucl. Med. 32, 2118\u20132123 (1991).","journal-title":"J. Nucl. Med."},{"key":"1167_CR68","first-page":"1085","volume":"40","author":"I Maruyama","year":"1999","unstructured":"Maruyama, I. et al. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study. J. Nucl. Med. 40, 1085\u20131090 (1999).","journal-title":"J. Nucl. Med."},{"key":"1167_CR69","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/0360-3016(91)90204-H","volume":"20","author":"JM Rozental","year":"1991","unstructured":"Rozental, J. M. et al. Early changes in tumor metabolism after treatment: the effects of stereotactic radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 20, 1053\u20131060 (1991).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1167_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216329","volume":"570","author":"MD Martino","year":"2023","unstructured":"Martino, M. D. et al. Radiation therapy promotes unsaturated fatty acids to maintain survival of glioblastoma. Cancer Lett. 570, 216329 (2023).","journal-title":"Cancer Lett."},{"key":"1167_CR71","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s43018-025-00905-6","volume":"6","author":"H Ni","year":"2025","unstructured":"Ni, H. et al. FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy. Nat. Cancer 6, 460\u2013473 (2025).","journal-title":"Nat. Cancer"},{"key":"1167_CR72","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41590-020-00861-6","volume":"22","author":"X Liu","year":"2021","unstructured":"Liu, X. & Peng, G. Mitochondria orchestrate T cell fate and function. Nat. Immunol. 22, 276\u2013278 (2021).","journal-title":"Nat. Immunol."},{"key":"1167_CR73","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.1717","volume":"29","author":"EP Papapetrou","year":"2011","unstructured":"Papapetrou, E. P. et al. Genomic safe harbors permit high \u03b2-globin transgene expression in thalassemia induced pluripotent stem cells. Nat. Biotechnol. 29, 73\u201378 (2011).","journal-title":"Nat. Biotechnol."},{"key":"1167_CR74","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/nprot.2009.95","volume":"4","author":"M DuPage","year":"2009","unstructured":"DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064\u20131072 (2009).","journal-title":"Nat. Protoc."},{"key":"1167_CR75","first-page":"319","volume":"49","author":"MH Ullman-Culler\u00e9","year":"1999","unstructured":"Ullman-Culler\u00e9, M. H. & Foltz, C. J. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab. Anim. Sci. 49, 319\u2013323 (1999).","journal-title":"Lab. Anim. Sci."},{"key":"1167_CR76","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2131229","volume":"11","author":"K Lontos","year":"2022","unstructured":"Lontos, K. et al. Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology. OncoImmunology 11, 2131229 (2022).","journal-title":"OncoImmunology"},{"key":"1167_CR77","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.1073\/pnas.92.15.6733","volume":"92","author":"I Rivi\u00e8re","year":"1995","unstructured":"Rivi\u00e8re, I., Brose, K. & Mulligan, R. C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl Acad. Sci. USA 92, 6733\u20136737 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR78","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279\u2013286 (2003).","journal-title":"Nat. Med."},{"key":"1167_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061338","volume":"8","author":"ML Davila","year":"2013","unstructured":"Davila, M. L., Kloss, C. C., Gunset, G. & Sadelain, M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE 8, e61338-14 (2013).","journal-title":"PLoS ONE"},{"key":"1167_CR80","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1016\/j.cell.2023.08.013","volume":"186","author":"F Blaeschke","year":"2023","unstructured":"Blaeschke, F. et al. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell 186, 4216\u20134234 (2023).","journal-title":"Cell"},{"key":"1167_CR81","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"1167_CR82","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-1-59745-409-4_7","volume":"506","author":"J Lee","year":"2009","unstructured":"Lee, J., Sadelain, M. & Brentjens, R. Retroviral transduction of murine primary T lymphocytes. Methods Mol. Biol. 506, 83\u201396 (2009).","journal-title":"Methods Mol. Biol."},{"key":"1167_CR83","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.2967\/jnumed.107.047324","volume":"49","author":"K Dobrenkov","year":"2008","unstructured":"Dobrenkov, K. et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J. Nucl. Med. 49, 1162\u20131170 (2008).","journal-title":"J. Nucl. Med."},{"key":"1167_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaf6925","volume":"1","author":"R Remark","year":"2016","unstructured":"Remark, R. et al. In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Sci. Immunol. 1, aaf6925 (2016).","journal-title":"Sci. Immunol."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01167-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01167-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01167-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:01:39Z","timestamp":1784901699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01167-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":84,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01167-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.19.624339","asserted-by":"object"}]},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.M. serves on the scientific advisory board and hold stock from Compugen, Dynavax, Asher Bio, Dren Bio, Genenta, Oncoresponse, Myeloid Therapeutics, DemBio and Owkin. M.M. serves on the scientific advisory board of Innate Pharma and VirBio. M.M. receives funding for contracted research from Genentech, Regeneron and Boehringer Ingelheim. None of these relationships are directly related to the present work. M.S. reports research funding from Juno Therapeutics, Fate Therapeutics, Takeda Pharmaceuticals and Atara Biotherapeutics, unrelated to the present research. M.S. and J.E. are scientific cofounders of Mnemo Therapeutics, unrelated to the present research. M.S. serves on the scientific advisory board of St. Jude Children Research Hospital. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}